NCT03006146View on ClinicalTrials.gov

Evaluation of a Single Dose of Inhaled Sargramostim in Patients With Autoimmune Pulmonary Alveolar Proteinosis

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 13, 2017

Primary Completion Date

June 7, 2021

Study Completion Date

June 7, 2021

Conditions
Autoimmune Pulmonary Alveolar Proteinosis
Interventions
DRUG

Sargramostim

Participants will receive a single administration of inhaled sargramostim (either 125 mcg or 250 mcg dose)

Trial Locations (2)

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

90095

University of California, Los Angeles, Los Altos

All Listed Sponsors
collaborator

Rare Diseases Clinical Research Network

NETWORK

collaborator

National Center for Advancing Translational Sciences (NCATS)

NIH

lead

Children's Hospital Medical Center, Cincinnati

OTHER

NCT03006146 - Evaluation of a Single Dose of Inhaled Sargramostim in Patients With Autoimmune Pulmonary Alveolar Proteinosis | Biotech Hunter | Biotech Hunter